Li Yun, Liu Honghui, Liu Na, Chen Lin, Liu Ruijie
Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Department of Gastroenterology Department, The Fourth Hospital of Changsha, Changsha, Hunan, 410017, China.
Mamm Genome. 2025 Mar;36(1):317-330. doi: 10.1007/s00335-024-10097-6. Epub 2024 Dec 30.
Immune cell infiltration in liver hepatocellular carcinoma (LIHC) is promising for immunotherapy. However, effective predictive markers to accurately predict a tumour's immune status are lacking. PSMD13, a native component of the 26 S proteasome subunit involved in intracellular metabolism, has an unclear association with cancer and immunity. Using bioinformatics analysis of data from the TCGA, we investigated the expression patterns, prognostic values, gene functions, and tumour immune relationships of PSMD13 in LIHC. We developed a prognostic model that incorporates PSMD13 for LIHC and validated the biological functions of PSMD13 in LIHC cells. Furthermore, we analysed the associations between PSMD13 expression and the tumour immune markers CD206 and CD8 in 101 paired liver tissues using immunohistochemistry. PSMD13 was upregulated in LIHC and served as a prognostic biomarker of LIHC. The knockdown of PMSD13 significantly affected the proliferation, migration, and colony formation of LIHC cells. PSMD13 was closely associated with the infiltration of M2 macrophages and the expression of various tumour immune checkpoints. Our study revealed that PSMD13 is a crucial component contributing to the malignant behaviour of LIHC, indicating its essential role in both the prognosis and potential immune microenvironment profile of LIHC.
肝细胞癌(LIHC)中的免疫细胞浸润对免疫治疗具有重要意义。然而,目前缺乏能够准确预测肿瘤免疫状态的有效预测标志物。PSMD13是参与细胞内代谢的26S蛋白酶体亚基的天然成分,其与癌症和免疫的关系尚不明确。通过对来自癌症基因组图谱(TCGA)的数据进行生物信息学分析,我们研究了PSMD13在LIHC中的表达模式、预后价值、基因功能以及肿瘤免疫关系。我们构建了一个纳入PSMD13的LIHC预后模型,并验证了PSMD13在LIHC细胞中的生物学功能。此外,我们使用免疫组织化学分析了101对肝组织中PSMD13表达与肿瘤免疫标志物CD206和CD8之间的关联。PSMD13在LIHC中上调,并可作为LIHC的预后生物标志物。敲低PSMD13显著影响LIHC细胞的增殖、迁移和集落形成。PSMD13与M2巨噬细胞的浸润以及各种肿瘤免疫检查点的表达密切相关。我们的研究表明,PSMD13是促成LIHC恶性行为的关键成分,表明其在LIHC的预后和潜在免疫微环境特征中均起重要作用。